Replacing a biotech legend, Gilead’s new CEO inherits sky-high expectations

Damian Garde John Martin, the man who led Gilead Sciences from the basements of biotech to the verge of Big Pharma, is stepping down after 20 years, with longtime lieutenant John Milligan ...

Struggling Eisai gets FDA approval for cancer drug Halaven for liposarcoma

Eric Palmer Japan's Eisai got a much-needed boost on Thursday when the FDA approved its cancer drug, Halaven, for treatment of liposarcoma for patients in which the cancer has advanced ...

Genentech snags a PhII-ready IL-33 asthma/COPD drug from Amgen

John Carroll Genentech has moved to the head of a small group of players in the anti-inflammatory arena, bagging rights to an antibody that scrambles the connection between IL-33 and ...

Merck sets $54K list price for hep C combo as it preps for battle with Gilead, AbbVie

Carly Helfand Industry watchers have long been speculating on how Merck would take on heavyweights Gilead and AbbVie when it priced its new hep C regimen. And now, they have their answer: ...

Venetoclax grabs third FDA ‘breakthrough’ for blood cancer

Alok Saboo AbbVie and Roche's venetoclax has received yet another accelerated review from the FDA–this time in patients with the most common type of acute leukemia. FierceBiotech ...

The top 10 (possible) blockbusters that (might) launch this year

John Carroll Can't get enough of sell-side estimates on the big new drugs in the late-stage pipeline? Then we have a treat for you today. FierceBiotech News

UPDATED: Big investor to activists: J&J should break up, so please put on the heat

Tracy Staton Should Johnson & Johnson join the Big Pharma split-up club? One of its major shareholders thinks so, and it's pressing activist investors to join the cause. FiercePharma ...

Trump crosses party lines to back Medicare drug-price negotiation

Alok Saboo Democratic presidential candidates Hillary Clinton and Bernie Sanders have already taken aim at pharma, talking up plans to give Medicare power to negotiate drug prices. ...

Kochenderfer: ‘I think the main focus of the CAR field will be autologous cells…’

John Carroll Yesterday there was a brief, digital dust-up on Twitter over an abstract circulating online on a CAR-T study undertaken from the NCI's James Kochenderfer, one of the ...

Revved-up Tecfidera sales power Biogen in Q4

Eric Palmer Biogen CEO George Scangos and his team tamped down investor expectations earlier this month at the J.P. Morgan Healthcare Conference, saying that the company faced headwinds. ...

Merck lines up for a quick approval with its C. diff therapy

Damian Garde Merck is nearing FDA approval for its Clostridium difficile-fighting antibody, picking up the agency's priority review designation with the promise of a shortened vetting ...

Novartis CEO Jimenez sees U.S. pricing power draining away

Carly Helfand Remember the days when drugmakers could raise prices without sparking political pushback? Novartis CEO Joe Jimenez does–and he says they're not coming back. FiercePharma ...
Page 1 of 1712345...10...Last »
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS